

# Clinical trials of repaglinide

TrialResults-center [www.trialresultscenter.org](http://www.trialresultscenter.org)

## 1 diabetes type 2

Trial	Treatments	Patients	Trials design and methods
<b>repaglinide vs ???</b>			
<b>YSRE0001</b> [NCT00336310] n=NA follow-up: 12 weeks	Repaglinide versus NA	-	double-blind Taiwan
<b>repaglinide vs control (add on MET)</b>			
<b>Moses , 1999</b> n=27/27 follow-up: 12 weeks	prestudy dose of metformin with the addition of repaglinide versus prestudy dose of metformin	patients with type 2 diabetes who had inadequate glycemic control (HbA1c >7.1% ) when receiving the antidiabetic agent metformin	Parallel groups open
<b>repaglinide vs glibenclamide</b>			
<b>Landgraf , 1999</b> n=NA follow-up: 14 weeks	repaglinide, administered preprandially three times daily versus glibenclamide, given preprandially once or twice daily	-	double-blind
<b>Marbury , 1999</b> n=NA	-	-	
<b>Wolffenbittel , 1999</b> n=211/109 follow-up: 1 year	repaglinide (0.5-4 mg t.i.d.) versus glyburide (1.75-10.5 mg daily)	-	double-blind
<b>repaglinide vs gliclazide</b>			
<b>AGEE-3783</b> [NCT01022762] n=NA follow-up:	repaglinide (1 mg repaglinide twice daily (weeks 0-4), titrated versus gliclazide (80 mg gliclazide once daily (weeks 0-4), titrated	Chinese subjects with type 2 diabetes who never have been treated with oral anti-diabetic drugs	China
<b>repaglinide vs glipizide</b>			
<b>Madsbad , 2001</b> n=256 follow-up: 1 year	repaglinide, 1-4 mg at mealtimes versus glipizide, 5-15 mg daily	-	double-blind

continued...

Trial	Treatments	Patients	Trials design and methods
<b>repaglinide + insulin vs insulin</b>			
AGEE-1524 [NCT00799448] n=NA follow-up:	repaglinide combined with insulin NPH versus biphasic human insulin 30 alone	type 2 diabetics inadequately controlled with sulfonylurea (SU) +/- biguanide therapy	open Greece
AGEE-3020 n=NA	-	-	
<b>repaglinide vs metformin</b>			
ReMet [NCT00118950] n=NA follow-up:	Repaglinide versus Metformin	Non-Obese Type 2 Diabetic Patients Uncontrolled by Diet	double-blind Denmark
Lund , 2007 n=NA follow-up:	repaglinide 2 mg thrice daily versus metformin 1 g twice daily	non-obese patients with type 2 diabetes	Cross over double-blind
<b>repaglinide + metformin vs metformin</b>			
AGEE-1411 [NCT01465152] n=NA follow-up:	-	-	open Spain
<b>repaglinide vs Metformin (add on insulin)</b>			
Reform [NCT00118963] n=NA follow-up:	Repaglinide + BIAsp30 versus Metformin + BIAsp30	non-obese patients with type-2-diabetes, uncontrolled on diet alone	double-blind
<b>repaglinide vs on top pioglitazone</b>			
Raskin , 2001 n=NA	-	-	
<b>repaglinide vs on top rosiglitazone</b>			
Raskin , 2001 n=NA	-	-	
<b>repaglinide vs on top troglitazone</b>			
Raskin , 2000 n=256 follow-up: 22 weeks	repaglinide (0.54.0 mg at meals), versus combination of repaglinide (14 mg at meals) and troglitazone (200600 mg once daily)	Patients with type 2 diabetes who had inadequate glycemic control (HbA1c 7.0% ) during previous monotherapy	open
<b>repaglinide vs placebo</b>			

continued...

<b>Trial</b>	<b>Treatments</b>	<b>Patients</b>	<b>Trials design and methods</b>
Goldberg , 1998 n=66/33 follow-up: 18 weeks	repaglinide versus placebo	patients with type 2 diabetes	Parallel groups double-blind
Jovanovic , 2000 n=286/75 follow-up: 24 weeks	repaglinide 1 mg (n = 140), or repaglinide 4 mg (n = 146) versus placebo	-	double-blind
Chuang , 1999 n=NA	-	-	
Bech , 2003 n=253 follow-up: 16 weeks	repaglinide initiated at 0.5 mg per meal, increased to 1 mg after 4 weeks if fasting plasma glucose exceeded 7.8 mmol/l. versus placebo	pharmacotherapy-naive patients with Type 2 diabetes	Parallel groups double-blind
Goldberg , 1998 n=66/33 follow-up:	repaglinide versus placebo	type 2 diabetes	Parallel groups double-blind
Jovanovic , 2000 n=286/75 follow-up: 24 weeks	repaglinide 1 mg or repaglinide 4 mg versus placebo	-	Parallel groups double-blind
<b>repaglinide vs placebo (on top bedtime NPH-insulin)</b>			
Landin-Olsson , 1999 n=NA	-	-	
<b>metformin + repaglinide vs repaglinide</b>			
AGEE-1411 [NCT01465152] n=NA follow-up: 24 weeks	metformin and repaglinide versus repaglinide	subjects with type 2 diabetes in which diet and exercise have failed	open Spain
<b>repaglinide + metformin vs repaglinide</b>			
AGEE-3705 [NCT00819741] n=NA follow-up:	repaglinide plus metformin versus repaglinide alone	Chinese subjects with type 2 diabetes having an HbA1c (glycosylated haemoglobin A1c) over 8.5 % and who never have taken oral sugar-lowering drugs before	open China
AGEE-3018 n=NA follow-up:	-	-	
<b>repaglinide + metformin vs rosiglitazone + metformin</b>			

continued...

Trial	Treatments	Patients	Trials design and methods
Raskin , 2009 [NCT00399711] n=NA follow-up: 26 weeks	repaglinide and metformin fixed dose combination tablet given as twice daily versus twice daily rosiglitazone and metformin fixed dose combination	subjects with type 2 diabetes currently on monotherapy	open USA
<b>repaglinide + metformin vs SU or MET</b>			
AGEE-3017 [NCT00568984] n=NA follow-up:	combination therapy of repaglinide and metformin versus conventional treatment with a sulphonylurea or metformin in monotherapy	-	China

More details and results :

- antidiabetic drugs for diabetes type 2 in all types of patients at <http://www.trialresultscenter.org/go-Q81>
- insulin secretagogues for diabetes type 2 in all type of patients at <http://www.trialresultscenter.org/go-Q409>
- antidiabetic drugs for diabetes type 2 in patients inadequately controlled on metformin at <http://www.trialresultscenter.org/go-Q509>
- antidiabetic drugs for diabetes type 2 in patients inadequately controlled on monotherapy at <http://www.trialresultscenter.org/go-Q512>
- insulin secretagogues - Meglitinides (glinides) for diabetes type 2 in all types of patients at <http://www.trialresultscenter.org/go-Q549>

## References

**YSRE0001, 0:**

**Moses, 1999:**

Moses R, Slobodniuk R, Boyages S, Colagiuri S, Kidson W, Carter J, Donnelly T, Moffitt P, Hopkins H Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 1999;22:119-24 [[10333912](#)]

Moses R Repaglinide in combination therapy with metformin in Type 2 diabetes. Exp Clin Endocrinol Diabetes 1999;107 Suppl 4:S136-9 [[10522839](#)] [10.1055/s-0029-1212169](#)

**Landgraf, 1999:**

Landgraf R, Bilo HJ, Mller PG A comparison of repaglinide and glibenclamide in the treatment of type 2 diabetic patients previously treated with sulphonylureas. Eur J Clin Pharmacol 1999;55:165-71 [[10379630](#)]

**Marbury, 1999:**

Marbury T, Huang WC, Strange P, Lebovitz H Repaglinide versus glyburide: a one-year comparison trial. *Diabetes Res Clin Pract* 1999;43:155-66 [[10369424](#)]

**Wolffenbittel, 1999:**

Wolffenbittel BH, Landgraf R A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Dutch and German Repaglinide Study Group. *Diabetes Care* 1999;22:463-7 [[10097930](#)]

**AGEE-3783, 0:****Madsbad, 2001:**

Madsbad S, Kilhovd B, Lager I, Mustajoki P, Dejgaard A Comparison between repaglinide and glipizide in Type 2 diabetes mellitus: a 1-year multicentre study. *Diabet Med* 2001;18:395-401 [[11472451](#)]

**AGEE-1524, 0:****AGEE-3020, :****ReMet, 0:****Lund, 2007:**

Lund SS, Tarnow L, Stehouwer CD, Schalkwijk CG, Frandsen M, Smidt UM, Pedersen O, Parving HH, Vaag A Targeting hyperglycaemia with either metformin or repaglinide in non-obese patients with type 2 diabetes: results from a randomized crossover trial. *Diabetes Obes Metab* 2007 May;9:394-407 [[17391168](#)]

**AGEE-1411, :****Reform, 0:**

Lund SS, Tarnow L, Frandsen M, Nielsen BB, Hansen BV, Pedersen O, Parving HH, Vaag AA Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial. *BMJ* 2009;339:b4324 [[19900993](#)]

**Raskin, 2001:**

Jovanovic L, Jain R, Greco S, et al. Repaglinide/pioglitazone combination therapy of type 2 diabetes *Diabetes* 2001; 50 Suppl. 2: A439

**Raskin, 2001:**

Raskin P, McGill J, Hale P, et al. Repaglinide/rosiglitazone combination therapy of type 2 diabetes *Diabetes* 2001; 50 Suppl. 2: A128

**Raskin, 2000:**

Raskin P, Jovanovic L, Berger S, Schwartz S, Woo V, Ratner R Repaglinide/troglitazone combination therapy: improved glycemic control in type 2 diabetes. *Diabetes Care* 2000;23:979-83 [[10895850](#)]

**Goldberg, 1998:**

Goldberg RB, Einhorn D, Lucas CP, Rendell MS, Damsbo P, Huang WC, Strange P, Brodows RG A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes. *Diabetes Care* 1998;21:1897-903 [[9802740](#)]

**Jovanovic, 2000:**

Jovanovic L, Dailey G 3rd, Huang WC, Strange P, Goldstein BJ Repaglinide in type 2 diabetes: a 24-week, fixed-dose efficacy and safety study. *J Clin Pharmacol* 2000;40:49-57 [[10631622](#)]

**Chuang, 1999:**

Chuang LM, Tai TY, Juang JH, et al. Effect of a prandial glucose regulator (NovoNorm) at two doses (0.5mg and 2.0mg) on glycemic control in type 2 diabetes in Taiwan *JAMA SE Asia* 1999; 51 (1): 22-5

**Bech, 2003:**

Bech P, Moses R, Gomis R The effect of prandial glucose regulation with repaglinide on treatment satisfaction, wellbeing and health status in patients with pharmacotherapy nave Type 2 diabetes: a placebo-controlled, multicentre study. Qual Life Res 2003;12:413-25 [[12797714](#)]

**Goldberg, 1998:**

Goldberg RB, Einhorn D, Lucas CP, Rendell MS, Damsbo P, Huang WC, Strange P, Brodows RG A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes. Diabetes Care 1998;21:1897-903 [[9802740](#)]

**Jovanovic, 2000:**

Jovanovic L, Dailey G 3rd, Huang WC, Strange P, Goldstein BJ Repaglinide in type 2 diabetes: a 24-week, fixed-dose efficacy and safety study. J Clin Pharmacol 2000;40:49-57 [[10631622](#)]

**Landin-Olsson, 1999:**

Landin-OlssonM, Brogard JMM, Eriksson J, et al. The efficacy of repaglinide administered in combination with bedtime NPH-insulin in patients with type 2 diabetes. A randomized, semi-blinded, parallel-group, multi-centre trial [abstract] Diabetes 1999 May; 48 Suppl. 1: A117

**AGEE-1411, 0:**

**AGEE-3705, 0:**

**AGEE-3018, :**

**Raskin , 2009:**

Raskin P, Lewin A, Reinhardt R, Lyness W Twice-daily dosing of a repaglinide/metformin fixed-dose combination tablet provides glycaemic control comparable to rosiglitazone/metformin tablet. Diabetes Obes Metab 2009 Sep;11:865-73 [[19476470](#)] [10.1111/j.1463-1326.2009.01062.x](#)

**AGEE-3017, 0:**

Entry terms: nateglinide, nateglinide, nate-glinide, senaglinide, IPCCPA, AY 4166, AY-4166, DJN 608, Starsis, Starlix, Novartis brand of nateglinide, A 4166, A-4166, Fastic, , repa-glinide, AG-EE 388 ZW, NovoNorm, GlucoNorm, Prandin, AG-EE 388, AG-EE 623 ZW,